Prognostic Significance of CK5/6 and GATA3 Expression in Recurrent Urothelial Carcinoma
محفوظ في:
| الحاوية / القاعدة: | Cancers vol. 17, no. 19 (2025), p. 3267-3289 |
|---|---|
| المؤلف الرئيسي: | |
| مؤلفون آخرون: | , , , , , |
| منشور في: |
MDPI AG
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | Citation/Abstract Full Text + Graphics Full Text - PDF |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
MARC
| LEADER | 00000nab a2200000uu 4500 | ||
|---|---|---|---|
| 001 | 3261055912 | ||
| 003 | UK-CbPIL | ||
| 022 | |a 2072-6694 | ||
| 024 | 7 | |a 10.3390/cancers17193267 |2 doi | |
| 035 | |a 3261055912 | ||
| 045 | 2 | |b d20250101 |b d20251231 | |
| 084 | |a 231438 |2 nlm | ||
| 100 | 1 | |a Lenda-Petrykowska Marzena |u Department of Vascular, General and Angiological Surgery, University Clinical Hospital No.2, Pomeranian Medical University in Szczecin, 72 Powstańców Wlkp. Al., 70-111 Szczecin, Poland; maszajn@gmail.com | |
| 245 | 1 | |a Prognostic Significance of CK5/6 and GATA3 Expression in Recurrent Urothelial Carcinoma | |
| 260 | |b MDPI AG |c 2025 | ||
| 513 | |a Journal Article | ||
| 520 | 3 | |a Background/Objectives: The study aimed to determine whether the expression of CK5/6 and GATA3 is altered in UCa recurrences and to evaluate disease-free survival (DFS) and overall survival (OS) according to CK5/6 and GATA3 expression. Methods: A retrospective study was performed in 77 patients with UCa. Surgery was performed in 35 patients. UCa recurrence was observed in 75% of patients. An immunohistochemical assessment of CK5/6 and GATA3 was performed in the primary and recurrent UCa groups. Results: CK5/6(+) in primary UCa was associated with a 73% probability of CK5/6(+) recurrence (p = 0.000005) and incidence at a younger age. CK5/6(−) in primary UCa was associated with an 84% probability of CK5/6(−) recurrence (p = 0.000005) and incidence at older age. A higher probability of UCa GATA3(+) recurrence was a significant independent factor associated with longer OS (p = 0.015). A greater probability of UCa CK5/6(+) recurrence was a significant independent factor associated with shorter OS (p = 0.044). Patients with CK5/6(+)-only UCa recurrences had significantly worse OS compared to UCa patients with at least one CK5/6(−) recurrence. Conclusions: 1. CK5/6 and GATA3 in UCa recurrences may differ from CK5/6 and GATA3 expression in primary UCa. Intensified oncological surveillance is suggested for patients with recurrent CK5/6(+) 2. Patients with at least one UCa CK5/6(−) recurrence have better prognosis compared to patients with only CK5/6(+) recurrences. | |
| 653 | |a Medical diagnosis | ||
| 653 | |a Urology | ||
| 653 | |a Urothelial carcinoma | ||
| 653 | |a Medical prognosis | ||
| 653 | |a Metastasis | ||
| 653 | |a GATA-3 protein | ||
| 653 | |a Cancer therapies | ||
| 653 | |a Prognosis | ||
| 653 | |a Biopsy | ||
| 653 | |a Oncology | ||
| 653 | |a Bladder cancer | ||
| 653 | |a Survival | ||
| 653 | |a Tumors | ||
| 653 | |a Urological surgery | ||
| 653 | |a Radiation therapy | ||
| 653 | |a Chemotherapy | ||
| 700 | 1 | |a Sulżyc-Bielicka Violetta |u Department of Medical Oncology, Pomeranian Medical University in Szczecin, 4 Arkońska St., 71-455 Szczecin, Poland | |
| 700 | 1 | |a Dobrzycki Wojciech |u Department of Pathomorphology, Provincial Specialist Hospital in Szczecin, 4 Arkońska St., 71-455 Szczecin, Poland | |
| 700 | 1 | |a Safranow Krzysztof |u Department of Biochemistry and Medical Chemistry, Pomeranian Medical University in Szczecin, 72 Powstańców Wlkp. Al., 70-111 Szczecin, Poland | |
| 700 | 1 | |a Świtała Jerzy |u Department of Urology, Provincial Specialist Hospital in Szczecin, 4 Arkońska St., 71-455 Szczecin, Poland | |
| 700 | 1 | |a Kostrzewa-Nowak Dorota |u Department of Clinical and Molecular Biochemistry, Pomeranian Medical University in Szczecin, 72 Powstańców Wlkp. Al., 70-111 Szczecin, Poland | |
| 700 | 1 | |a Bielicki Paweł |u Department of Radiotherapy, Pomeranian Medical University in Szczecin, 22 Strzałowska St., 71-730 Szczecin, Poland; pawelbielicki68@gmail.com | |
| 773 | 0 | |t Cancers |g vol. 17, no. 19 (2025), p. 3267-3289 | |
| 786 | 0 | |d ProQuest |t Biological Science Database | |
| 856 | 4 | 1 | |3 Citation/Abstract |u https://www.proquest.com/docview/3261055912/abstract/embedded/6A8EOT78XXH2IG52?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text + Graphics |u https://www.proquest.com/docview/3261055912/fulltextwithgraphics/embedded/6A8EOT78XXH2IG52?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text - PDF |u https://www.proquest.com/docview/3261055912/fulltextPDF/embedded/6A8EOT78XXH2IG52?source=fedsrch |